FDA grants TTP399, an oral once-daily glucokinase activator, type 1 diabetes drug breakthrough therapy designation

This was based on data from the Phase II SimpliciT-1 study that demonstrated treatment with 800mg of TTP399 resulted in statistically significant decreases in HbA1c. It showed a clinically relevant reduction by about 40% in frequency of hypoglycaemia vs placebo.

Source:

Biospace Inc.